AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
2023 · Hepatology · 1,402 citations
https://doi.org/10.1097/hep.0000000000000466
L
Lipika Goyal
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
607
Papers
18.4K
Citations
57
h-index
130
i10-index
Lipika Goyal is an academic researcher from Harvard University. The author has contributed to research in topics: Fibroblast Growth Factor Research & Cholangiocarcinoma and Gallbladder Cancer Studies & Eosinophilic Disorders and Syndromes. The author has an h-index of 57, co-authored 516 publications.
ORCID: 0000-0002-9777-6221Papers by this author
worksIvosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
2020 · The Lancet Oncology · 995 citations
https://doi.org/10.1016/s1470-2045(20)30157-1
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
2023 · New England Journal of Medicine · 465 citations
https://doi.org/10.1056/nejmoa2206834
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
2021 · The Lancet. Gastroenterology & hepatology · 398 citations
https://doi.org/10.1016/s2468-1253(21)00196-5
Immunology and immunotherapy of cholangiocarcinoma
2023 · Nature Reviews Gastroenterology & Hepatology · 164 citations
https://doi.org/10.1038/s41575-022-00741-4
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
2020 · Annals of Oncology · 144 citations
https://doi.org/10.1016/j.annonc.2020.06.018
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat